Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Income from Continuing Operations (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Income from Continuing Operations for 15 consecutive years, with 153700000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 49.08% year-over-year to 153700000.0, compared with a TTM value of 478600000.0 through Dec 2025, up 40.23%, and an annual FY2025 reading of 478600000.0, up 40.23% over the prior year.
  • Income from Continuing Operations was 153700000.0 for Q4 2025 at Neurocrine Biosciences, down from 209500000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 209500000.0 in Q3 2025 and bottomed at 76600000.0 in Q1 2023.
  • Average Income from Continuing Operations over 4 years is 79133333.33, with a median of 83100000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations surged 156.66% in 2024, then tumbled 81.8% in 2025.
  • Year by year, Income from Continuing Operations stood at 30500000.0 in 2021, then skyrocketed by 339.67% to 134100000.0 in 2023, then decreased by 23.12% to 103100000.0 in 2024, then skyrocketed by 49.08% to 153700000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for NBIX at 153700000.0 in Q4 2025, 209500000.0 in Q3 2025, and 107500000.0 in Q2 2025.